The effects of zidovudine in the subset of infants infected with human immunodeficiency virus type-1 (Pediatric AIDS Clinical Trials Group Protocol 076)

Citation
Gd. Mcsherry et al., The effects of zidovudine in the subset of infants infected with human immunodeficiency virus type-1 (Pediatric AIDS Clinical Trials Group Protocol 076), J PEDIAT, 134(6), 1999, pp. 717-724
Citations number
32
Categorie Soggetti
Pediatrics,"Medical Research General Topics
Journal title
JOURNAL OF PEDIATRICS
ISSN journal
00223476 → ACNP
Volume
134
Issue
6
Year of publication
1999
Pages
717 - 724
Database
ISI
SICI code
0022-3476(199906)134:6<717:TEOZIT>2.0.ZU;2-U
Abstract
Objective: To describe the effect of zidovudine on human immunodeficiency v irus type I (HIV-1) and on the course of disease in infants who became infe cted while they and their mothers received zidovudine preventive therapy or placebo in Pediatric AIDS Clinical Trials Group Protocol 076. Study design: Observational substudy of a multicenter, randomized, double-b lind, placebo-controlled trial. Methods: We compared the progression of disease, timing of HIV-1 transmissi on, and the plasma HIV-1 RNA level in infected infants of mother-infant pai rs who were randomly assigned to receive zidovudine (n = 14) or placebo (n = 43). The development of genotypic zidovudine resistance was assessed amon g infected infants in the zidovudine treatment group. Results: In this limited study, zidovudine therapy during pregnancy and lab or and in the neonatal period for 6 weeks failed to have a major effect on rapid progression of disease, timing of transmission, and viral replication in HIV-infected infants. When the zidovudine treatment regimen failed to p revent maternal-infant transmission of HIV-1, resistance to zidovudine did not develop during study treatment. Conclusions: Our study supports the safety of zidovudine use in pregnancy a nd in the newborn period but demonstrates the continued need for more poten t antiretroviral treatment of the infected infant.